159 related articles for article (PubMed ID: 14723007)
1. Treatment strategies for myeloma bone disease.
Berenson JR
Oncology (Williston Park); 2003 Dec; 17(12):1678, 1681-2. PubMed ID: 14723007
[No Abstract] [Full Text] [Related]
2. [The treatment of osseous multiple myeloma; possible value of plasmapheresis].
Revol L; Favre-Gilly J; Bryon PA; Guyon M; Fiere D
Lyon Med; 1972 May; 227(10):901-3. PubMed ID: 5053536
[No Abstract] [Full Text] [Related]
3. Updates in the treatment of multiple myeloma.
Berenson JR
Clin Adv Hematol Oncol; 2012 Oct; 10(10):667-9. PubMed ID: 23187773
[No Abstract] [Full Text] [Related]
4. Nephrotic syndrome after treatment with pamidronate.
Markowitz GS; Fine PL; D'agati VD
Am J Kidney Dis; 2002 May; 39(5):1118-22. PubMed ID: 11979358
[No Abstract] [Full Text] [Related]
5. Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.
Henley D; Kaye J; Walsh J; Cull G
Intern Med J; 2005 Dec; 35(12):726-8. PubMed ID: 16313549
[TBL] [Abstract][Full Text] [Related]
6. Bone metastases from primary hepatocellular carcinoma simulating multiple myeloma.
Doval DC; Bhatia K; Vaid AK; Prabhash K; Jena A; Hazarika D
Hepatobiliary Pancreat Dis Int; 2005 May; 4(2):308-10. PubMed ID: 15908337
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates, cancer, and osteonecrosis--a single practice experience.
Guarino MJ; Hill CE; Patel K
Del Med J; 2005 May; 77(5):181-7. PubMed ID: 15957261
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Marx RE; Sawatari Y; Fortin M; Broumand V
J Oral Maxillofac Surg; 2005 Nov; 63(11):1567-75. PubMed ID: 16243172
[TBL] [Abstract][Full Text] [Related]
9. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms behind the anti-tumour effects of zoledronic acid use in multiple myeloma.
Ararat E; Sahin I; Ozdemir E; Altundag K
Br J Haematol; 2010 Dec; 151(5):530-1. PubMed ID: 20880117
[No Abstract] [Full Text] [Related]
11. Solitary extramedullary and bone plasmacytomas versus multiple myeloma with extramedullary manifestation.
Nair B
Oncology (Williston Park); 2010 Aug; 24(9):836. PubMed ID: 20923038
[No Abstract] [Full Text] [Related]
12. The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates.
Kraj M; Pogłód R; Maj S; Owczarska K
Acta Pol Pharm; 2006; 63(5):450-2. PubMed ID: 17357613
[No Abstract] [Full Text] [Related]
13. Plasma cell neoplasms. Review of disease progression and report of a new variant.
Nolan KD; Mone MC; Nelson EW
Surg Oncol; 2005 Aug; 14(2):85-90. PubMed ID: 15993050
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
Musto P; Petrucci MT; Bringhen S; Guglielmelli T; Caravita T; Bongarzoni V; Andriani A; D'Arena G; Balleari E; Pietrantuono G; Boccadoro M; Palumbo A;
Cancer; 2008 Oct; 113(7):1588-95. PubMed ID: 18683218
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
Tiffany NM; Wersinger EM; Garzotto M; Beer TM
Urology; 2004 May; 63(5):934-9. PubMed ID: 15134984
[TBL] [Abstract][Full Text] [Related]
16. [Myeloma: diagnosis and treatment].
Bauters F
Lille Med; 1972; 17(7):1032-40. PubMed ID: 4637671
[No Abstract] [Full Text] [Related]
17. Osteonecrosis of the jaw and bisphosphonates.
Maerevoet M; Martin C; Duck L
N Engl J Med; 2005 Jul; 353(1):99-102; discussion 99-102. PubMed ID: 16003838
[No Abstract] [Full Text] [Related]
18. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
[TBL] [Abstract][Full Text] [Related]
19. Severe clavicular disease in multiple myeloma.
Ferretti A; De Angelis G; Petrucci MT
Br J Haematol; 2016 Jun; 173(6):820. PubMed ID: 27161803
[No Abstract] [Full Text] [Related]
20. Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases.
Smith A; Kressley A; Saif MW
JOP; 2009 Mar; 10(2):212-4. PubMed ID: 19287122
[No Abstract] [Full Text] [Related]
[Next] [New Search]
